Questions for the Board at the AGM

I am thinking we should collate a few questions that should be directed to the board at the upcoming AGM:

I'll start:
1: How many of the 650-odd global MSC trials has Cynata approached about its Cymerus technology?
2: How many large pharmacy firms has Cynata presented to in the last 2 years?
3: What is the current state of play with the MOU with Cellularity?
4: How many large financial institutions have approached Cynata after one of its many company presentations at events like the recent Rodman & Renshaw Investor Conference?
5: Can the board provide a detailed update on the Licencing Model strategy we are told we are pursuing.